Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings Results

Key Points

• Supernus Pharmaceuticals reported earnings of $0.78 per share, exceeding the consensus estimate of $0.47 by $0.31 for the quarter.
• The company's stock rose by 1.3% to hit $37.53, with a trading volume significantly higher than its average.
• Analysts have upgraded Supernus Pharmaceuticals' stock ratings, with Cantor Fitzgerald setting a new price target of $42.00, indicating positive growth expectations.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) announced its earnings results on Tuesday. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.31, Zacks reports. Supernus Pharmaceuticals had a return on equity of 12.23% and a net margin of 9.27%. Supernus Pharmaceuticals updated its FY 2025 guidance to EPS.

Supernus Pharmaceuticals Stock Up 1.3%

Supernus Pharmaceuticals stock traded up $0.48 during trading hours on Tuesday, hitting $37.53. The stock had a trading volume of 1,132,005 shares, compared to its average volume of 595,254. The company has a 50-day moving average of $32.74 and a two-hundred day moving average of $33.33. The company has a market cap of $2.10 billion, a PE ratio of 33.81 and a beta of 0.74. Supernus Pharmaceuticals has a fifty-two week low of $27.58 and a fifty-two week high of $40.28.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently modified their holdings of SUPN. Millennium Management LLC increased its holdings in Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company's stock valued at $4,695,000 after purchasing an additional 112,886 shares in the last quarter. Jane Street Group LLC bought a new position in Supernus Pharmaceuticals in the 1st quarter valued at $3,641,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Supernus Pharmaceuticals by 7.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 107,789 shares of the specialty pharmaceutical company's stock valued at $3,530,000 after buying an additional 7,769 shares during the last quarter. AQR Capital Management LLC boosted its position in Supernus Pharmaceuticals by 35.2% in the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company's stock valued at $2,791,000 after buying an additional 22,182 shares during the last quarter. Finally, Empowered Funds LLC boosted its position in Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company's stock valued at $1,573,000 after buying an additional 6,619 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Cantor Fitzgerald raised Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 price objective on the stock in a research note on Wednesday, July 30th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.